Ovarian cancer symptoms: The ‘patchy’ rash on your skin you should never ignore
OVARIAN CANCER symptoms may be difficult to spot in its early stages, but can include stomach bloating and passing more urine than normal. You could also be at risk of ovarian cancer if you develop this unusual rash on your skin. Should you consider speaking to a doctor? (Source: Daily Express - Health)
Source: Daily Express - Health - September 17, 2020 Category: Consumer Health News Source Type: news

CU researchers now better understand ovarian cancer tumors and treatment outcomes
(University of Colorado Anschutz Medical Campus) After nearly four years of work, a group of researchers and clinicians from CU published a paper this week in the Clinical Cancer Research that shares findings from research looking at how the composition of ovarian cancer tumors changes during chemotherapy and contributes to therapeutic response. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 15, 2020 Category: Cancer & Oncology Source Type: news

Mayo Clinic Q and A: Ovarian cancer symptoms and treatment options
DEAR MAYO CLINIC: A woman I work with was diagnosed with ovarian cancer two years ago at 60. She reportedly was having a lot of abdominal bloating and pain on one side after meals. I heard she had a recurrence recently, and I am starting to worry since I have recently begun experiencing bloating after [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 15, 2020 Category: Databases & Libraries Source Type: news

Researchers develop rapid test for ovarian cancer detection
(University of Turku) Researchers at the University of Turku, Finland, have developed a test for ovarian cancer detection with a sensitivity 4.5 times higher than that of the conventional laboratory test. The simple lateral flow test is based on rapid detection of abnormal sugar structures directly from the blood sample. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 11, 2020 Category: Cancer & Oncology Source Type: news

Veterinary college team IDs gene that drives ovarian cancer
(Cornell University) scientists at the College of Veterinary Medicine have collaborated on a study that pinpoints which specific genes drive - or delay - high-grade serious ovarian carcinoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 11, 2020 Category: International Medicine & Public Health Source Type: news

Gene Signature May Improve Prognostication in Ovarian Cancer Gene Signature May Improve Prognostication in Ovarian Cancer
A new gene expression signature could improve on conventional risk factors related to estimating prognosis and selecting treatment in patients with high-grade serous ovarian cancer, a study suggests.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 5, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Science Saturday: Could population genetic screening improve public health?
Hereditary BRCA-related breast and ovarian cancer, Lynch syndrome and familial hypercholesterolemia are estimated to be relatively prevalent in the general population but poorly found using traditional risk screening. In a typical medical practice, genetic testing for these conditions is based on personal or family history, ethnic background or other demographic characteristics, that may not always be easily or accurately gathered by a physician. [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 5, 2020 Category: Databases & Libraries Source Type: news

Hair Dye and Cancer Study'Offers Some Reassurance'Hair Dye and Cancer Study'Offers Some Reassurance '
The largest study of its kind found that, with the exception of breast and ovarian cancers, there is no tie between use of permanent hair dye and cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 4, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Peer Review Finds EPA ’s Asbestos Risk Evaluation Flawed
The Science Advisory Committee on Chemicals found considerable failings and an underestimation of danger to the general public in a draft risk evaluation of asbestos submitted earlier this year by the U.S. Environmental Protection Agency. SACC, which serves as a scientific, peer-review mechanism for the EPA, released its recommendations last week in the ongoing governmental reevaluation of asbestos. This is the latest step in the amended Toxic Substances Control Act that requires the EPA to conduct evaluations on specific chemicals to determine whether they present unreasonable risk under conditions of use. The committee w...
Source: Asbestos and Mesothelioma News - September 2, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Model Better Predicts Lung Cancer Risk for African Americans
TUESDAY, Sept. 1, 2020 -- The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Model 2012 (PLCOm2012) risk prediction model is more sensitive for identifying African American ever-smokers for lung cancer screening than the U.S.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 1, 2020 Category: Pharmaceuticals Source Type: news

Experiences With Cancer, Captured in Works of Art
The program Brushes With Cancer pairs patients with artists whose works make visible a disease that can be invisible and isolating. (Source: NYT Health)
Source: NYT Health - August 26, 2020 Category: Consumer Health News Authors: Susan Gubar Tags: Art Breast Cancer Hodgkin ' s Lymphoma Ovarian Cancer Coronavirus (2019-nCoV) Source Type: news

New treatment possibilities for young women diagnosed with rare form of ovarian cancer
(University of British Columbia) A recent finding by researchers at the BC Cancer Research Institute and the University of British Columbia (UBC) may offer a new treatment possibility for people diagnosed with a rare and aggressive form of ovarian cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 26, 2020 Category: International Medicine & Public Health Source Type: news

New surgical approach for women at risk of ovarian cancer
(Queen Mary University of London) A new two-stage surgical approach for cancer prevention is highly acceptable among premenopausal women at high risk of ovarian cancer, according to research led by Queen Mary University of London. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 24, 2020 Category: Cancer & Oncology Source Type: news

New operation cuts the risk of ovarian cancer... and an early menopause
Surgeons first carry out an operation to remove the Fallopian tubes, where most ovarian cancers are found. The ovaries themselves are spared, and taken out years later. (Source: the Mail online | Health)
Source: the Mail online | Health - August 22, 2020 Category: Consumer Health News Source Type: news

Ovarian Cancer Trials: The Good News and the Bad News Ovarian Cancer Trials: The Good News and the Bad News
Dr Maurie Markman describes two trials that may shift the paradigm for ovarian cancer treatment but also notes that we are continuing to let down our patients by failing to test forBRCA mutations.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 19, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Degradation of 5hmC-marked stalled replication forks by APE1 causes genomic instability
Synthetic lethality between poly(ADP-ribose) polymerase (PARP) inhibition and BRCA deficiency is exploited to treat breast and ovarian tumors. However, resistance to PARP inhibitors (PARPis) is common. To identify potential resistance mechanisms, we performed a genome-wide RNAi screen in BRCA2-deficient mouse embryonic stem cells and validation in KB2P1.21 mouse mammary tumor cells. We found that resistance to multiple PARPi emerged with reduced expression of TET2 (ten-eleven translocation), which promotes DNA demethylation by oxidizing 5-methylcytosine (5mC) to 5-hydroxymethycytosine (5hmC) and other products. TET2 knockd...
Source: Signal Transduction Knowledge Environment - August 18, 2020 Category: Science Authors: Kharat, S. S., Ding, X., Swaminathan, D., Suresh, A., Singh, M., Sengodan, S. K., Burkett, S., Marks, H., Pamala, C., He, Y., Fox, S. D., Buehler, E. C., Muegge, K., Martin, S. E., Sharan, S. K. Tags: STKE Research Articles Source Type: news

Tumour gene test could help to predict ovarian cancer prognosis
(University of New South Wales) A global team of medical researchers led by UNSW have developed a test that could help to predict survival for women diagnosed with ovarian cancer, and pave the way towards personalised treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 17, 2020 Category: Cancer & Oncology Source Type: news

Can You Be Fully Cured of Ovarian Cancer?
Title: Can You Be Fully Cured of Ovarian Cancer?Category: Procedures and TestsCreated: 8/14/2020 12:00:00 AMLast Editorial Review: 8/14/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 14, 2020 Category: Cancer & Oncology Source Type: news

Exploring connections between ovarian cancer and blood cells
(Texas A&M University) Recent discoveries made by researchers at Texas A&M University could change the way ovarian cancer is understood and treated. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 14, 2020 Category: International Medicine & Public Health Source Type: news

What Are the Symptoms of Stage 1 Ovarian Cancer?
Title: What Are the Symptoms of Stage 1 Ovarian Cancer?Category: Diseases and ConditionsCreated: 8/13/2020 12:00:00 AMLast Editorial Review: 8/13/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 13, 2020 Category: Cancer & Oncology Source Type: news

Age, education, and surgical history affect hormone use after oophorectomy
(The North American Menopause Society (NAMS)) CLEVELAND, Ohio (August 12, 2020)--Removal of the ovaries before natural menopause (surgical menopause) often exacerbates menopause symptoms and places women at increased risk for heart disease, osteoporosis, and cognitive decline. A new study identified the frequency of hormone therapy (HT) use and factors that determine who is more likely to use hormones after oophorectomy to manage symptoms. Study results are published online today in Menopause, the journal of The North American Menopause Society (NAMS). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 12, 2020 Category: Cancer & Oncology Source Type: news

First US clinical trial testing efficacy of delivering aerosolized chemotherapy
(City of Hope) City of Hope surgical researchers are the first in the nation to open a clinical trial that could one day become an effective way to deliver chemotherapy to abdominal cancer patients who currently have very few treatment options. Ovarian, uterine, gastric and colorectal cancers can be difficult to treat using traditional intravenous chemotherapy, especially when the tumors spread to a thin layer of tissue that lines the abdomen called the peritoneum. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 11, 2020 Category: Cancer & Oncology Source Type: news

CUNY ISPH study sheds new light on how ovarian cancer grows and evolves
(CUNY Graduate School of Public Health and Health Policy) In a paper published in the journal Cancer Research, professor Levi Waldron, post-doctoral fellow Ludwig Geistlinger, and colleagues at the Institute for Implementation Science in Population Health (ISPH) at the CUNY Graduate School of Public Health and Health Policy (CUNY SPH) provide new insights into how ovarian cancer grows and evolves within a person. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 5, 2020 Category: Cancer & Oncology Source Type: news

Mesothelioma T-Cell Therapy Shows Early Effectiveness in Trial
A mesothelioma clinical trial involving genetically modified T cells has opened to considerable acclaim, shrinking tumors in the first five patients who were treated. The phase I portion of the clinical trial is designed to define the safety profile and optimal dosage level of TC-210, a novel immunotherapy targeting mesothelin, a cell-surface protein often overexpressed in several cancers. While T cell modifications in the laboratory are proving safe and well tolerated, the initial signs of consistent efficacy became an early bonus in phase I. Four of the patients treated had mesothelioma. The fifth had ovarian cancer. All...
Source: Asbestos and Mesothelioma News - August 4, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
             Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory t...
Source: Roche Media News - August 3, 2020 Category: Pharmaceuticals Source Type: news

Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
             Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory t...
Source: Roche Investor Update - August 3, 2020 Category: Pharmaceuticals Source Type: news

Most women treated in New York City for gynecologic cancers
(NYU Langone Health / NYU School of Medicine) Women receiving standard treatment in New York City for ovarian, uterine, and cervical cancers are not at increased risk of being hospitalized for or dying from COVID-19 due to their cancer, a new study shows. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 30, 2020 Category: International Medicine & Public Health Source Type: news

A new way to target cancers using 'synthetic lethality'
(University of California - San Diego) Researchers at Ludwig Institute for Cancer Research and University of California San Diego School of Medicine report that inhibiting a key enzyme caused human cancer cells associated with two major types of breast and ovarian cancer to die and in mouse studies reduced tumor growth. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 27, 2020 Category: Cancer & Oncology Source Type: news

Merck, Targovax Team Up for New Mesothelioma Clinical Trial
Standard-of-care treatment for malignant mesothelioma could change significantly, depending upon the results of an upcoming clinical trial of two immunotherapy agents used in combination with chemotherapy. The mesothelioma clinical trial will involve pembrolizumab, also known by the brand name Keytruda, and its synergy with ONCOS-102, a lesser-known, genetically modified adenovirus. Individually, both have shown modest efficacy for mesothelioma patients when used with chemotherapy. Together, there is potential for a much greater impact in significantly extending patient survival. The clinical trial is a partnership between...
Source: Asbestos and Mesothelioma News - July 22, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Ashion Analytics announces innovative cancer treatment partnership with Elevation Oncology
(The Translational Genomics Research Institute) Ashion Analytics today announced a partnership with Elevation Oncology, a clinical stage biopharmaceutical company, focused on the matching of patients with tumors harboring an NRG1 gene fusion identified using Ashion's proprietary GEM ExTra ® test with CRESTONE, a registration-directed Phase 2 study sponsored by Elevation Oncology. NRG1 gene fusions are a rare genomic alteration implicated as a driver of tumorigenesis and growth across many types of solid tumors, including lung, breast, pancreatic, ovarian, and colorectal cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 22, 2020 Category: Cancer & Oncology Source Type: news

Oncotarget: Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2)
(Impact Journals LLC) The cover for issue 29 of Oncotarget features Figure 5, " In vivo effects of treatment with L-Grb2 in combination with anti-angiogenic therapy in an ovarian tumor model, " by Lara, et al. which reported that adaptor proteins such as growth factor receptor-bound protein-2 play important roles in cancer cell signaling. In the present study, the authors examined the biological effects of liposomal antisense oligodeoxynucleotide that blocks Grb2 expression in gynecologic cancer models. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 22, 2020 Category: Cancer & Oncology Source Type: news

Widening cancer gene testing is cost effective and could prevent millions of cancer cases
(Queen Mary University of London) Screening entire populations for breast and ovarian cancer gene mutations could prevent millions more breast and ovarian cancer cases across the world compared to current clinical practice, according to an international study led by Queen Mary University of London. The research also shows that it is cost effective in high and upper-middle income countries. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 16, 2020 Category: Cancer & Oncology Source Type: news

Could the willow help us fight cancer?
An ingredient in its bark led to aspirin, now researchers are looking into the properties of another compound in the treeWillow trees are a pharmaceutical treasure trove. The ancient Egyptians used its bark for relieving pain, inflammation and fevers, and science has since shown these medical powers came from an ingredient called salicin, named aftersalix, the Latin name for the tree. That discovery eventually led to the manufacture of aspirin, one of the most widely used medicines in the world.Recently another potential drug has been found in willow, one with anti-cancer powers. Scientists atRothamsted Research in Hertfor...
Source: Guardian Unlimited Science - July 14, 2020 Category: Science Authors: Paul Simons Tags: Science Trees and forests Environment UK news Cancer research Medical research Source Type: news

Ovarian cancer treatments must restart immediately, charity warns
The charity Target Ovarian Cancer has published a report calling for treatment for the disease, which is often diagnosed in its later stages, to be restarted as soon as possible to save valuable time. (Source: the Mail online | Health)
Source: the Mail online | Health - July 14, 2020 Category: Consumer Health News Source Type: news

Heroic woman, 48, who died from ovarian cancer spent last months of life devising awareness campaign
Vicky Jacobs, 48, created a multimedia campaign to raise awareness of the disease that was to take her life, ovarian cancer. The campaign features Kate Winslet who lost her mother Sally to the cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - July 14, 2020 Category: Consumer Health News Source Type: news

Nonprofits Call for Worldwide Halt of J & J Baby Powder Sales
National advocacy group Black Women for Wellness joined more than 170 other nonprofits from 51 countries last week in demanding that Johnson & Johnson stop the worldwide distribution of its iconic Johnson’s Baby Powder. The demand for a global distribution ban stems from the potential for asbestos in talc, which has led to various cancers and thousands of personal injury lawsuits. A majority of talc cases pertain to women and ovarian cancer. A small percentage of the legal claims involve mesothelioma, a rare and aggressive cancer caused primarily by the inhalation or ingestion of asbestos fibers. Johnson & Jo...
Source: Asbestos and Mesothelioma News - July 13, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers a...
Source: Roche Media News - July 13, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers a...
Source: Roche Investor Update - July 13, 2020 Category: Pharmaceuticals Source Type: news

TGen identifies immune effects of drug in aggressive ovarian cancer striking young women
(The Translational Genomics Research Institute) A drug known as SP-2577 could help enable the body's own immune system to attack ovarian cancer, according to a study led by TGen. Published today in the scientific journal PLOS ONE, the study builds on years of research led by Dr. Jeffrey Trent, TGen President and Research Director, into a type of ovarian cancer known as Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT), a cancer that usually strikes girls and young women. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 10, 2020 Category: Cancer & Oncology Source Type: news

NCI Studying New Mesothelioma Immunotherapy Combination
Patients with mesothelioma are being recruited by the National Cancer Institute for a phase II clinical trial using a novel immunotoxin prior to pembrolizumab, a combination that has shown preliminary evidence of efficacy. This promising mesothelioma clinical trial involves the drug LMB-100, designed to make immunotherapy agents such as pembrolizumab, otherwise known as Keytruda, more effective. NCI’s trial includes separate cohorts for pleural and peritoneal types of mesothelioma. “This is a very good option for these patients,” medical oncologist Dr. Raffit Hassan, an acclaimed investigator at the Natio...
Source: Asbestos and Mesothelioma News - July 8, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Ovarian cancer symptoms: The sign when it comes to sex that can signal the deadly disease
OVARIAN cancer can be difficult to recognise, but the condition can put women completely off of sex. So how do you know if it's a lacklustre libido or something more sinister? (Source: Daily Express - Health)
Source: Daily Express - Health - July 8, 2020 Category: Consumer Health News Source Type: news

Rise in Talc Cases Reshapes Traditional Asbestos Litigation
A recent rise in litigation linking cosmetic talc with mesothelioma and lung cancer will continue throughout 2020, despite companies abandoning the product in the hope of avoiding costly verdicts. The number of legal cases is expected to increase by 10% this year, building on an 11% rise in 2019, according to KCIC, a well-regarded consulting firm based in Washington, D.C., that manages asbestos product liabilities. “A new trend we have started to see is talc allegations showing up in traditional asbestos complaints,” said KCIC Vice President Michelle Potter during a recent webinar that looked at past litigation...
Source: Asbestos and Mesothelioma News - July 7, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Oncotarget: Clonality and antigen-specific responses shape prognostic effects
(Impact Journals LLC) Oncotarget Volume 11, Issue 27 reported that to delineate the complexity of anti-tumor T-cell responses, the author's utilized a computational method for de novo assembly of sequences from CDR3 regions of 369 high-grade serous ovarian cancers from TCGA, and then applied deep TCR-sequencing for analyses of paired tumor and peripheral blood specimens from an independent cohort of 99 ovarian cancer patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2020 Category: Cancer & Oncology Source Type: news

Protein linked to cancer acts as a viscous glue in cell division
(Rensselaer Polytechnic Institute) The protein PRC1, a telltale sign in many cancer types including prostate, ovarian, and breast cancer, act as a " viscous glue " during cell division, precisely controlling the speed at which two sets of DNA are separated as a single cell divides. The finding could explain why too much or too little PRC1 disrupts that process and causes genome errors linked to cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2020 Category: Cancer & Oncology Source Type: news

Breast cancer drug, olaparib, depletes store of immature eggs in mouse ovaries
(European Society of Human Reproduction and Embryology) Australian researchers have shown for the first time that a new drug used to treat breast cancer patients damages the store of immature eggs in the ovaries of mice. Authors of the study published in Human Reproduction journal say fertility counselling should be considered for young women who may be about to be treated with olaparib. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - June 30, 2020 Category: International Medicine & Public Health Source Type: news

Johnson & Johnson Talc-Asbestos Verdict Upheld, Award Cut
The Missouri Court of Appeals upheld a landmark jury verdict that said long-term use of Johnson & Johnson’s talc products, possibly contaminated with asbestos fibers, had caused ovarian cancer in 22 women. The Court of Appeals also reduced the earlier, record-setting award for punitive and compensatory damages from $4.69 billion to $2.1 billion. A Johnson & Johnson spokesperson said the company would appeal again with the Supreme Court of Missouri. Johnson & Johnson has been flooded with more than 19,000 lawsuits in U.S. state and federal courts over its talc products, the majority of which pertain to ova...
Source: Asbestos and Mesothelioma News - June 25, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Highlights in Ovarian Cancer From ASCO 2020 Highlights in Ovarian Cancer From ASCO 2020
Dr Maurie Markman reports on key ovarian cancer presentations from ASCO 2020, including the eagerly awaited DESKTOP III trial, results of maintenance olaparib from the SOLO-2, and the PAOLA-1 study.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 24, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

J & J Ordered to Pay $2.1 Billion in Talcum Product Lawsuit
WEDNESDAY, June 24, 2020 -- Johnson& Johnson and a subsidiary must pay $2.1 billion in damages to women who said their ovarian cancers were caused by the company's baby powder and other talcum products, a Missouri appeals court ruled... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 24, 2020 Category: Pharmaceuticals Source Type: news

J & amp;J Ordered to Pay & #36;2.1 Billion in Talcum Product Lawsuit
WEDNESDAY, June 24, 2020 -- Johnson& Johnson and a subsidiary must pay $2.1 billion in damages to women who said their ovarian cancers were caused by the company's baby powder and other talcum products, a Missouri appeals court ruled... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 24, 2020 Category: Pharmaceuticals Source Type: news

Missouri court slashes Johnson & Johnson talcum powder verdict to $2.1B
The Missouri Court of Appeals on Tuesday upheld a 2018 verdict against Johnson& Johnson that its talcum powder caused cancer in 22 women. But it also cut by more than half the original $4.69 billion judgement against the company, reducing it to $2.1 billion. In July 2018, a jury in St. Louis Circuit Court awarded a share of the damages to the 22 women who said Johnson& Johnson talcum powder caused their ovarian cancer and that the company failed to warn consumers about cancer risks from its products. The… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 24, 2020 Category: Biotechnology Authors: Erik Siemers Source Type: news